Short answer
Olema Pharmaceuticals, Inc. (OLMA) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$63M
- −44.3% YoY · −19.0% QoQ
- EPS (diluted)
- −$0.60
- −17.6% YoY · −15.4% QoQ
Source: XBRL data from the Olema Pharmaceuticals, Inc. (OLMA) Q2 2026 10-Q on SEC EDGAR. USD.
Olema Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No product revenue in either quarter; product sales not yet commercialized
- R&D expense $57.8M vs $43.9M YoY, up 32%
- G&A expense $9.4M vs $4.0M YoY, up 137%
- Net loss $63.2M vs $43.8M YoY, up 44%
- OPERA-01 enrollment complete; top-line results expected Q1 2027 and potential launch in 2028
Risk Factors
- Newly added financing risk: Fourth Amendment added Olema Oncology International Limited as a secured guarantor on July 1, 2026
- Materially updated debt risk: Loan maturity extended to January 1, 2029, with potential extension to July 1, 2029
- Regulatory risk: No pivotal trial completed or NDA submitted, leaving approval for palazestrant and OP-3136 uncertain
- Clinical risk: Palazestrant remains the lead candidate, with failure delaying commercialization and revenue generation
- Financial risk: Net loss $63.2 million in Q2 2026 versus $43.8 million in Q2 2025, with accumulated deficit $713.8 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Olema Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.